Mineralocorticoid resistance.
Zennaro MC.
Steroids. 1996 Apr;61(4):189-92. doi: 10.1016/0039-128x(96)00011-6.
Primary Generalized Glucocorticoid Resistance Syndrome.
Kino T, Nicolaides NC, Charmandari E, Chrousos GP.
2024 May 19. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–.
Low-Renin Hypertension.
Athimulam S, Lazik N, Bancos I.
Endocrinol Metab Clin North Am. 2019 Dec;48(4):701-715. doi: 10.1016/j.ecl.2019.08.003. Epub 2019 Sep 25.
Mineralocorticoid resistance.
Geller DS.
Clin Endocrinol (Oxf). 2005 May;62(5):513-20. doi: 10.1111/j.1365-2265.2005.02229.x.
Pseudohypoaldosteronism.
Riepe FG.
Endocr Dev. 2013;24:86-95. doi: 10.1159/000342508. Epub 2013 Feb 1.
Interactions cardiorénales.
Rossignol P, Juillard L.
Nephrol Ther. 2017 Jun;13(6S):6S11-6S15. doi: 10.1016/S1769-7255(18)30035-X.
Résistances aux hormones stéroïdes : physiologie et pathologie: Pathophysiology of Steroid Resistance Syndrome.
Ramos N, Lombès M.
Ann Endocrinol (Paris). 2016 Oct;77 Suppl 1:S1-S10. doi: 10.1016/S0003-4266(17)30072-0.
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME.
Circ Res. 2015 Mar 13;116(6):991-1006. doi: 10.1161/CIRCRESAHA.116.305697.
Abiraterone-Induced Endocrinopathies.
Decamps S, Lis R, Ekanayake P.
JCEM Case Rep. 2023 Apr 13;1(2):luad039. doi: 10.1210/jcemcr/luad039. eCollection 2023 Mar.
Glucocorticoid resistance.
van Rossum EFC, van den Akker ELT.
Endocr Dev. 2011;20:127-136. doi: 10.1159/000321234. Epub 2010 Dec 16.
